journal
https://read.qxmd.com/read/38924687/anti-drug-antibody-therapeutic-drug-monitoring-status-update-and-future-directions-in-spondyloarthritis
#21
EDITORIAL
Dae Hyun Yoo
No abstract text is available yet for this article.
June 24, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38924652/autologous-cd19-targeting-car-t-cells-in-refractory-juvenile-dermatomyositis
#22
JOURNAL ARTICLE
Rebecca Nicolai, Pietro Merli, Patricia Moran Alvarez, Claudia Bracaglia, Francesca Del Bufalo, Emiliano Marasco, Ivan Caiello, Giusi Prencipe, Mattia Algeri, Maria G Cefalo, Marco Becilli, Concetta Quintarelli, Matilde Sinibaldi, Linda Hanssens, Fabrizio De Benedetti, Franco Locatelli
OBJECTIVES: To report safety and efficacy of CD19-targeting CAR T cells in a child with refractory juvenile dermatomyositis (JDM). PATIENTS AND METHODS: We describe the case of a 12-year-old Caucasian boy with severe, chronically active JDM, refractory to multiple immunosuppressive treatment lines, including B-cell depletion with rituximab. The patient received a single infusion of fresh, autologous, second-generation anti-CD19 CAR T-cell product (lentiviral vector) manufactured on the Prodigy device (1x106 CAR T cells/kg), after lymphodepletion with cyclophosphamide (1000 mg/m2 over 2 days) and fludarabine (90 mg/m2 over 3 days)...
June 24, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38923871/efficacy-and-safety-of-upadacitinib-or-elsubrutinib-alone-or-in-combination-for-systemic-lupus-erythematosus-a-phase-2-randomized-controlled-trial
#23
JOURNAL ARTICLE
Joan T Merrill, Yoshiya Tanaka, David D'Cruz, Karina Vila-Rivera, Daniel Siri, Xiaofeng Zeng, Amit Saxena, Martin Aringer, Kristin M D'Silva, Ling Cheng, Mohamed-Eslam F Mohamed, Lucia Siovitz, Sumit Bhatnagar, Marie-Claude Gaudreau, Thao T Doan, Alan Friedman
OBJECTIVE: The 48-week, phase 2 SLEek study (NCT03978520) evaluated the efficacy and safety of upadacitinib (Janus kinase inhibitor) and elsubrutinib (Bruton's tyrosine kinase inhibitor) alone or in combination (ABBV-599) in adults with moderately to severely active systemic lupus erythematosus (SLE). METHODS: Patients were randomized 1:1:1:1:1 to once-daily (QD) ABBV-599 high dose (HD; elsubrutinib 60mg + upadacitinib 30mg), ABBV-599 low dose (LD; elsubrutinib 60mg + upadacitinib 15mg), elsubrutinib 60mg, upadacitinib 30mg, or placebo...
June 24, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38923870/association-of-cardiovascular-outcomes-with-low-dose-glucocorticoid-use-in-patients-with-rheumatoid-arthritis
#24
JOURNAL ARTICLE
Brian W Coburn, Joshua F Baker, Jesse Y Hsu, Qufei Wu, Fenglong Xie, Jeffrey R Curtis, Michael D George
OBJECTIVE: Many guidelines recommend limiting glucocorticoids in patients with rheumatoid arthritis (RA), but 40% of patients remain on glucocorticoids long-term. We evaluated the cardiovascular risk of long-term glucocorticoid use by studying patients on stable disease modifying anti-rheumatic drugs (DMARDs). METHODS: Using two claims databases, we identified patients with RA on stable DMARD therapy for >180 days. Proportional hazards models with inverse probability weights and clustering to account multiple observations were used to estimate the effect of glucocorticoid dose on composite cardiovascular outcomes (stroke or myocardial infarction)...
June 24, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38923852/the-hydroxychloroquine-conundrum-striking-the-right-balance-between-safety-and-efficacy-in-rheumatology-practice
#25
EDITORIAL
Jinoos Yazdany, Stephen Shiboski, Gabriela Schmajuk
No abstract text is available yet for this article.
June 24, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38923837/mek1-2-and-erk1-2-mediated-lung-endothelial-injury-and-altered-hemostasis-promote-diffuse-alveolar-hemorrhage-in-murine-lupus
#26
JOURNAL ARTICLE
Haoyang Zhuang, Shuhong Han, Neil S Harris, Westley H Reeves
OBJECTIVE: About 3% of lupus patients develop severe diffuse alveolar hemorrhage (DAH) with pulmonary vasculitis. B6 mice with pristane-induced lupus also develop DAH, but BALB/c mice are resistant. DAH is independent of TLR signaling and other inflammatory pathways. This study examined the role of the mitogen-activated protein kinase pathway (MEK1/2-ERK1/2, JNK, p38). METHODS: B6 and BALB/c mice were treated with pristane ± inhibitors of MEK1/2 (trametinib/GSK1120212, "GSK"), ERK1/2 (SCH772984, "SCH"), JNK, or p38...
June 24, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38923410/highlighting-the-need-for-consensus-diverse-classification-strategies-in-contemporary-research-on-idiopathic-inflammatory-myopathies
#27
LETTER
Keeran Shivakumar, Emily Sun, Ocean Ma, Latika Gupta, Jessica Day
No abstract text is available yet for this article.
June 24, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38923299/authors-reply
#28
LETTER
Lindsay N Helget, Ted R Mikuls
No abstract text is available yet for this article.
June 24, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38923259/a-multiomic-analysis-to-identify-drivers-of-subclinical-vascular-disease-in-systemic-lupus-erythematosus
#29
JOURNAL ARTICLE
Christopher Oliveira, Yenealem Temesgen-Oyelakin, Mohammad Naqi, Michael Davis, Faiza Naz, Stefania Dell'Orso, Stephen Brooks, Skyler Kuhn, Tom Hill, Xiaobai Li, Nidhi Patel, Philip Pare, Massimo Gadina, Sarthak Gupta, Nehal Mehta, Sarfaraz A Hasni, Mariana J Kaplan
BACKGROUND: SLE increases cardiovascular disease (CVD) risk, not accounted by traditional risk factors. Characterization of blood immunological signatures that associate with subclinical CVD and predict its progression has been challenging and may help identify subgroups at risk. METHODS: SLE patients (n=77) and healthy controls (HC n=27) underwent assessments of arterial stiffness, vascular wall inflammation and coronary atherosclerosis burden with cardio-ankle vascular index (CAVI), fluorodeoxyglucose-positron emission tomography/CT (TBR), and coronary CT-angiography, respectively...
June 24, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38831643/hydroxychloroquine-dose-and-hospitalizations-for-active-lupus
#30
JOURNAL ARTICLE
Jacquelyn Nestor, Hyon Choi, Christian Mancini, Baijun Zhou, Yuqing Zhang, Karen H Costenbader, April Jorge
OBJECTIVES: We sought to determine the impact of hydroxychloroquine (HCQ) dose on the risk of hospitalizations for systemic lupus erythematosus (SLE). METHODS: We conducted a case-crossover study within an academic health system, including patients with SLE who used HCQ and had ≥ 1 hospitalization for active SLE between January 2011 and December 2021. Case periods ended in hospitalization for SLE, whereas control periods did not. The exposures were the average weight-based HCQ dose, categorized as ≤5 or >5 mg/kg/day, and non-weight-based HCQ dose, categorized as <400 or 400 mg/day, assessed during each 6-month case or control period...
June 3, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38801195/long-term-follow-up-of-anti-infliximab-antibodies-in-radiographic-axial-spondyloarthritis-patients-a-marker-of-drug-survival-and-tapering
#31
JOURNAL ARTICLE
Clarissa Q Pimentel, Ana Cristina Medeiros-Ribeiro, Andrea Y Shimabuco, Percival D Sampaio-Barros, Júlio César B Moraes, Claudia G Schainberg, Celio Roberto Gonçalves, Elaine P Leon, Léonard De Vinci K Kupa, Sandra G Pasoto, Nádia E Aikawa, Clovis A Silva, Eloisa Bonfa, Carla G S Saad
OBJECTIVES: To evaluate the influence of anti-infliximab antibodies (anti-IFX) on 3 different points of care: response/tolerance to infliximab (IFX), tapering strategy, and in a subsequent treatment with a second tumor necrosis factor inhibitor (TNFi). METHODS: A prospective cohort of 60 radiographic axial spondyloarthritis (r-axSpA) patients under IFX were evaluated retrospectively regarding clinical/laboratorial data, IFX levels and anti-IFX, at baseline, after 6, 12-14, 22-24, 48-54, 96-102 weeks and before tapering or switching...
May 27, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38782598/minor-genetic-overlap-between-rheumatoid-arthritis-myocardial-infarction-and-its-risk-determinants
#32
JOURNAL ARTICLE
Anton Öberg Sysojev, Lars Alfredsson, Lars Klareskog, Gilad N Silberberg, Saedis Saevarsdottir, Leonid Padyukov, Patrik K E Magnusson, Johan Askling, Helga Westerlind
OBJECTIVE: To investigate whether a shared genetic susceptibility exists between rheumatoid arthritis (RA) and myocardial infarction (MI) - including major MI risk factors - and to quantify the degree of any such overlap. METHODS: Genome-wide association study (GWAS) data for RA was constructed from a sample of 26,637 Swedish RA cases and RA-free controls. For MI, GWAS data was obtained from a previously published meta-analysis. Genome-wide genetic correlation was estimated via LD score regression...
May 23, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38782587/transcriptomic-profiling-and-immuno-histological-characterization-of-synovial-biopsies-in-juvenile-idiopathic-arthritis-jia-suggest-two-broad-categories-with-significant-overlap-with-rheumatoid-arthritis-ra
#33
JOURNAL ARTICLE
Clément Triaille, Gaëlle Tilman, Charlotte A Baert, Tatiana Sokolova, Axelle Loriot, Adrien Nzeusseu-Toukap, Laurent Meric de Bellefon, Christine Galant, Cécile Boulanger, Joao E Fonseca, Caroline Bouzin, Patrick Durez, Bernard R Lauwerys, Nisha Limaye
OBJECTIVES: To characterize transcriptomic profiles and immune cell composition and distribution in Juvenile Idiopathic Arthritis (JIA) synovial biopsies, assess for associations of these features with clinical parameters, and compare JIA and Rheumatoid Arthritis (RA) synovial features. METHODS: RNASeq was performed on 24 samples, with pathway analysis and inference of relative abundance of immune cell subsets based on gene expression data. Two multiplex fluorescence immunohistochemistry (IHC) panels were performed on 28 samples (including 13 on which RNASeq was performed), staining for CD206- classical and CD206+ non-classical macrophages, CD8+ and CD4+ T and B lymphocytes...
May 23, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38770592/phase-2-trial-of-deucravacitinib-in-psoriatic-arthritis-biomarkers-associated-with-disease-activity-pharmacodynamics-and-clinical-responses
#34
JOURNAL ARTICLE
Oliver FitzGerald, Dafna D Gladman, Philip J Mease, Christopher Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
OBJECTIVE: To evaluate the association of serum biomarkers with baseline psoriatic arthritis (PsA) disease activity, pharmacodynamic effects of deucravacitinib on biomarker levels, and relationship between biomarkers and clinical responses to deucravacitinib. METHODS: The phase 2 trial (NCT03881059) randomized 203 patients with PsA 1:1:1 to placebo, deucravacitinib 6 mg once daily (QD), or deucravacitinib 12 mg QD. Serum biomarkers associated with the IL-23 pathway (IL-17A, BD-2, and IL-19), Type I interferon pathway, inflammation, and collagen matrix turnover were measured by immunoassay...
May 21, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38766897/impact-of-glucocorticoid-dose-on-complete-response-serious-infections-and-mortality-during-the-initial-therapy-of-lupus-nephritis-a-systematic-review-and-meta-analysis-of-the-control-arms-of-randomized-controlled-trials
#35
JOURNAL ARTICLE
Gabriel Figueroa-Parra, María C Cuéllar-Gutiérrez, Mariana González-Treviño, Alain Sanchez-Rodriguez, Jaime Flores-Gouyonnet, José A Meade-Aguilar, Larry J Prokop, M Hassan Murad, María Dall'Era, Brad H Rovin, Frédéric Houssiau, Farah Tamirou, Fernando C Fervenza, Cynthia S Crowson, Michael S Putman, Alí Duarte-García
OBJECTIVE: Our objective was to evaluate the effect of glucocorticoid regimens on renal response, infections, and mortality among patients with lupus nephritis (LN). METHODS: We performed a systematic review and meta-analysis of the control arms of randomized clinical trials (RCTs). We included RCTs of biopsy-proven LN that used a protocolized regimen of glucocorticoids in combination with mycophenolic acid analogs or cyclophosphamide and reported the outcomes of complete response (CR), serious infections, and death...
May 20, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38766737/antibodies-to-malondialdehyde-acetaldehyde-adduct-are-associated-with-prevalent-and-incident-rheumatoid-arthritis-associated-interstitial-lung-disease-in-us-veterans
#36
JOURNAL ARTICLE
Nozima Aripova, Geoffrey M Thiele, Michael J Duryee, Carlos D Hunter, Yangyuna Yang, Punyasha Roul, Dana P Ascherman, Scott M Matson, Gary Kunkel, Grant W Cannon, Katherine D Wysham, Gail S Kerr, Paul A Monach, Joshua F Baker, Jill A Poole, Ted R Mikuls, Bryant R England
OBJECTIVE: The objective of this study is to determine the associations of protein-specific anti-malondialdehyde-acetaldehyde (MAA) antibodies with prevalent and incident rheumatoid arthritis-interstitial lung disease (RA-ILD). METHODS: Within a multicenter, prospective cohort of US veterans with RA, RA-ILD was validated by medical record review of clinical diagnoses, chest imaging, and pathology. Serum antibodies to MAA-albumin, MAA-collagen, MAA-fibrinogen, and MAA-vimentin (IgA, IgM, and IgG) were measured by a standardized enzyme-linked immunosorbent assay...
May 20, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38751108/unveiling-metabolic-similarities-of-entheses-in-psoriasis-and-psoriatic-arthritis-patients-using-non-invasive-in-vivo-imaging-results-from-the-mapsa-study
#37
JOURNAL ARTICLE
Filippo Fagni, Koray Tascilar, Rita Noversa de Sousa, Sara Bayat, Lukas Sollfrank, Arnd Kleyer, Michael Sticherling, Adrian P Regensburger, Ferdinand Knieling, Markus F Neurath, Georg Schett, Maximilian Waldner, David Simon
OBJECTIVES: To assess and compare molecular tissue changes at the entheses in patients with psoriasis (PsO), psoriatic arthritis (PsA), and healthy controls (HC) in vivo using multispectral optoacoustic tomography (MSOT) and to describe their relationship with clinical and ultrasound findings of enthesitis. METHODS: A cross-sectional study (MAPSA) in bDMARD-naïve PsA and PsO patients and HC was performed. Participants underwent clinical, ultrasonographic and MSOT examination of six entheses (lateral humeral epicondyle, distal patellar tendon attachment, Achilles tendon attachment)...
May 15, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38751102/american-college-of-rheumatology-white-paper-the-effects-of-climate-change-on-rheumatic-conditions-an-evolving-landscape-and-a-path-forward
#38
JOURNAL ARTICLE
Paul F Dellaripa, Lily H Sung, Paul A Bain, Cristina Lanata, Ashira Blazar, Frederick W Miller, Candace H Feldman
OBJECTIVE: Increases in global temperatures and extreme weather events associated with climate change have complex yet poorly understood detrimental impacts on human health. We reviewed the current published literature on climate change-related effects and rheumatic conditions. METHODS: To summarize our current understanding of the likely effects of climate change, including increased air pollution, on rheumatic disease, we searched the published, peer-reviewed English-language literature from January 2000 to December 2022...
May 15, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38751101/integrating-radiomics-and-neural-networks-for-knee-osteoarthritis-incidence-prediction
#39
JOURNAL ARTICLE
Shengfa Li, Peihua Cao, Jia Li, Tianyu Chen, Ping Luo, Guangfeng Ruan, Yan Zhang, Xiaoshuai Wang, Weiyu Han, Zhaohua Zhu, Qin Dang, Qianyi Wang, Mengdi Zhang, Qiushun Bai, Zhiyi Chai, Hao Yang, Haowei Chen, Mingze Tang, Arafat Akbar, Alexander Tack, David J Hunter, Changhai Ding
OBJECTIVE: Accurately predicting knee osteoarthritis (KOA) is essential for early detection and personalized treatment. We aimed to develop and test an MRI-based Joint Space Radiomic Model (JS-RM) to predict radiographic KOA incidence through neural networks by integrating meniscus and femorotibial cartilage radiomic features. METHODS: In the Osteoarthritis Initiative cohort, knees without radiographic KOA at baseline but at high risk for radiographic KOA were included...
May 15, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38699822/risk-of-gastrointestinal-perforation-in-patients-with-rheumatic-diseases-exposed-to-janus-kinase-inhibitors-versus-adalimumab-a-nationwide-cohort-study
#40
JOURNAL ARTICLE
Lea Hoisnard, Antoine Meyer, Rosemary Dray-Spira, Alain Weill, Mahmoud Zureik, Emilie Sbidian
OBJECTIVE: To compare the risk of gastrointestinal perforation (GIP), a rare but serious adverse event, in patients who a JAK inhibitor (JAKi; tofacitinib, baricitinib, upadacitinib, or filgotinib) versus adalimumab (tumor necrosis factor inhibitor) among a comprehensive real-world population of patients with rheumatic diseases. METHODS: We conducted a nationwide population-based cohort study of the French national health data system, the exposed group that received a JAKi and the comparison group adalimumab...
May 3, 2024: Arthritis & Rheumatology
journal
journal
48327
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.